These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 20190794)

  • 1. Hormonal therapies: ADT for prostate cancer: true love or heartbreak?
    Efstathiou JA; Shipley WU; Zietman AL; Smith MR
    Nat Rev Clin Oncol; 2010 Mar; 7(3):130-2. PubMed ID: 20190794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate cancer: Say no to ADT for localized disease.
    Payton S
    Nat Rev Urol; 2014 Sep; 11(9):487. PubMed ID: 25069734
    [No Abstract]   [Full Text] [Related]  

  • 3. Treating asymptomatic patients with hormone-refractory prostate cancer: hormonal manipulations for the urologist.
    Boudreaux KJ; Chang SS
    BJU Int; 2008 Mar; 101(6):671-4. PubMed ID: 18070172
    [No Abstract]   [Full Text] [Related]  

  • 4. Primary androgen deprivation therapy in men with prostate cancer.
    Laufman L
    JAMA; 2009 Jan; 301(1):35; author reply 35. PubMed ID: 19126809
    [No Abstract]   [Full Text] [Related]  

  • 5. Prostate cancer: is androgen-deprivation therapy chosen wisely?
    Villanueva MT
    Nat Rev Clin Oncol; 2014 Sep; 11(9):501. PubMed ID: 25073003
    [No Abstract]   [Full Text] [Related]  

  • 6. Prostate cancer: Why statins are beneficial.
    Thoma C
    Nat Rev Urol; 2015 Jul; 12(7):360. PubMed ID: 26032545
    [No Abstract]   [Full Text] [Related]  

  • 7. Hormone-refractory prostate cancer: what have we learned?
    Wirth MP
    BJU Int; 2007 Jul; 100 Suppl 2():56-9. PubMed ID: 17594362
    [No Abstract]   [Full Text] [Related]  

  • 8. Progress in Understanding What Is Being Statin(ed) in Prostate Cancer.
    Ramos JD; Yu EY
    JAMA Oncol; 2015 Jul; 1(4):428-30. PubMed ID: 26181247
    [No Abstract]   [Full Text] [Related]  

  • 9. Measuring the effectiveness of androgen-deprivation therapy for prostate cancer in the medicare population: adequate data are neither the same as nor the enemy of perfect data.
    Trinh QD; Schrag D
    JAMA Intern Med; 2014 Sep; 174(9):1468-9. PubMed ID: 25023522
    [No Abstract]   [Full Text] [Related]  

  • 10. Intermittent androgen suppression. Too good to be true?
    Abrahamsson PA
    Scand J Urol Nephrol Suppl; 1999; 203():45-9. PubMed ID: 10636570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hormone refractory prostate cancer and the prevention of the adverse effects of the treatment].
    Zgliczyński S; Borówka A
    Endokrynol Pol; 2005; 56(3):223. PubMed ID: 16350713
    [No Abstract]   [Full Text] [Related]  

  • 12. [Basic and clinical characteristics of flutamide].
    Suzuki K; Nakazato H; Kurokawa K; Yamanaka H
    Nihon Rinsho; 2000 Jul; 58 Suppl():211-5. PubMed ID: 11022716
    [No Abstract]   [Full Text] [Related]  

  • 13. Androgen deprivation and antagonism in the treatment of advanced prostatic carcinoma.
    Gibbs SJ; Plowman PN
    Clin Oncol (R Coll Radiol); 1996; 8(6):346-52. PubMed ID: 8973848
    [No Abstract]   [Full Text] [Related]  

  • 14. Survival outcomes in men receiving androgen-deprivation therapy as primary or salvage treatment for localized or advanced prostate cancer: 20-year single-centre experience.
    DiBlasio CJ; Malcolm JB; Hammett J; Wan JY; Aleman MA; Patterson AL; Wake RW; Derweesh IH
    BJU Int; 2009 Nov; 104(9):1208-14. PubMed ID: 19388987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Failure to report financial disclosure information.
    Lu-Yao G; Albertsen P; Shih W; Yao SL
    JAMA; 2009 Jan; 301(1):35-6. PubMed ID: 19126808
    [No Abstract]   [Full Text] [Related]  

  • 16. Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis.
    Rydzewska LHM; Burdett S; Vale CL; Clarke NW; Fizazi K; Kheoh T; Mason MD; Miladinovic B; James ND; Parmar MKB; Spears MR; Sweeney CJ; Sydes MR; Tran N; Tierney JF;
    Eur J Cancer; 2017 Oct; 84():88-101. PubMed ID: 28800492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Manipulation of androgens and alterations in the androgen receptor axis in prostate cancer.
    Nguyen MM; Wang Z
    Minerva Urol Nefrol; 2008 Mar; 60(1):15-29. PubMed ID: 18427432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statin Use at the Time of Initiation of Androgen Deprivation Therapy and Time to Progression in Patients With Hormone-Sensitive Prostate Cancer.
    Harshman LC; Wang X; Nakabayashi M; Xie W; Valenca L; Werner L; Yu Y; Kantoff AM; Sweeney CJ; Mucci LA; Pomerantz M; Lee GS; Kantoff PW
    JAMA Oncol; 2015 Jul; 1(4):495-504. PubMed ID: 26181260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Somatostatin analogs in the combined treatment of patients with hormone-resistant prostate cancer].
    Kaprin AD; Gafanov PA; Fastovets SV
    Vopr Onkol; 2009; 55(4):474-6. PubMed ID: 19947374
    [No Abstract]   [Full Text] [Related]  

  • 20. Intermittent androgen ablation as a treatment for prostate cancer.
    Wolff JM
    Front Radiat Ther Oncol; 2002; 36():66-71. PubMed ID: 11842756
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.